Last updated on March 2019

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS)


Brief description of study

The primary endpoint of this study is the time to first  occurrence of any component of the composite endpoint, as adjudicated by the Clinical  Endpoint Committee (CEC). Components of the primary endpoint are:              

  • Cardiovascular (CV) death     
  • Resuscitated cardiac arrest   
  • Non-­fatal MI        
  • Non-­fatal stroke 

Clinical Study Identifier: TX201699

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.